المؤلفون: Cavacini LA; Beth Israel Deaconess Medical Center, 21-27 Burlington Avenue, Room 556, Boston, MA 02215, USA. lcavacin@caregroup.harvard.edu, Duval M, Eder JP, Posner MR

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2002 Feb; Vol. 8 (2), pp. 368-73.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Cancer Vaccines*, Cell Membrane/*immunology , Epitopes/*chemistry , Prostate-Specific Antigen/*metabolism , Prostate-Specific Antigen/*pharmacology , Prostatic Neoplasms/*immunology , Prostatic Neoplasms/*prevention & control, Cell Membrane/metabolism ; Flow Cytometry ; Humans ; Immunoglobulin G/blood ; Male ; Prostate-Specific Antigen/chemistry ; Time Factors ; Tumor Cells, Cultured

مستخلص: Purpose: Prostate cancer consistently remains a difficult clinical problem. The development of novel therapy strategies for effective control and treatment of prostate cancer is essential. The prostate represents a unique site for immunotherapy, in part because prostate-specific immunity would most probably be without significant long-term sequellae. Antibodies and cell-mediated immunity, induced by either active or passive immunization, represent potential means to specifically target prostate tumor cells.
Experimental Design: The serum IgG response to cell surface antigens expressed on LNCAP [prostate-specific antigen (PSA)-positive] and PC-3 (PSA-negative) were analyzed in individuals with advanced disease receiving vaccinia- or fowlpox-expressed PSA (v-PSA or f-PSA, respectively) by flow cytometry.
Results: Sera from all seven patients in a Phase I study of v-PSA, collected prior to the third immunization, reacted with both prostate tumor cell lines. The majority of individuals (n = 12) in a Phase II trial of v-PSA and f-PSA developed sustainable antibody responses to cell surface antigens on the prostate tumor cell lines. The magnitude and kinetics of these responses were dependent on the immunization schedule. Of importance, the baseline serum of only one of nine patients tested had reactivity with nonprostate tumor cell lines. Sera from three normal males also lacked reactivity with prostate tumor cells.
Conclusions: PSA vaccine constructs are immunogenic and induce antibody responses to a multitude of surface antigens on prostate tumor cell lines by epitope or determinant spreading after stimulation of the immune system by PSA immunization.